Honeywell Stock: The 3-Way Breakup Is Done — It Beat and Raised, So Why We Say HOLD

Honeywell (HON) Q2 2026 — Honeywell (HON) — now branded Honeywell Technologies and a pure-play automation company after spinning off Aerospace (HONA) on June 29, 2026 and Solstice Advanced Materials (SOLS) in late 2025 — reported a clean Q2 2026: adjusted EPS of $1.95 beat the ~$1.80 estimate (+10% YoY) on sales of $5.19B (+3% reported, +4% organic), segment margin expanded 100 bps to 19.0%, and orders jumped 16% to a ~$20B backlog. Management RAISED full-year 2026 guidance — adjusted EPS to $8.05–$8.35 (up 25–29%) and organic growth to 3–4%. Ignore the $16.65 GAAP EPS — it's a one-time gain from deconsolidating Quantinuum. The catch: at ~30x forward earnings with only mid-single-digit organic growth and ~$20B net debt, even our compounder-leaning owner-earnings DCF lands fair value near $205 — below the ~$243 price. Our call: HOLD, 3/5. We're more cautious than the Street's ~$257 target (Buy). Honeywell just finished one of the most ambitious breakups in industrial history. Over the past year it spun off Advanced Materials as Solstice (SOLS) and then, on June 29, 2026, spun off Honeywell Aerospace as its own public company (HONA) — leaving what still trades as HON a focused, ~$77B pure-play automation company across Building Automation, Industrial Automation, and Process Automation & Technology. Q2 2026, the first quarter on the new standalone basis, was genuinely strong: adjusted EPS of $1.95 beat the ~$1.80 estimate (+10% YoY), sales rose 3% (4% organic) to $5.19B, segment margin expanded 100 bps to 19.0%, and orders jumped 16% to a ~$20B backlog — with Building Automation the crown jewel at a 27% margin and +9% organic. Management RAISED full-year guidance to adjusted EPS of $8.05–$8.35 (up 25–29%). One trap to avoid: the $16.65 GAAP EPS is a mirage from the one-time Quantinuum deconsolidation gain — the $1.95 adjusted figure is what counts. So the debate isn't quality — it's price. The stock has re-rated to ~30x forward earnings on the clean-compounder story, yet underlying organic growth is only 3–4%, two of three segments had soft spots (Process organic -1%, Industrial reported -5%), and ~$20B of net debt ($28.7B gross) sits on the balance sheet. Even leaning toward the optimistic compounder path at a quality discount rate, our owner-earnings DCF lands fair value near $205 — below today's ~$243. A wonderful business with no margin of safety. Our call: HOLD, 3/5. We're notably more cautious than the Street's ~$257 target (Buy, 19 of 29 analysts). Own it for the quality, add on real weakness toward $200, and watch organic growth and de-levering. Not financial advice. THE CALL: HOLD (3/5, A GREAT BUSINESS AT A FULL PRICE — A CLEAN BEAT-AND-RAISE WITH NO MARGIN OF SAFETY) — base-case value ~$205 vs ~$243 today. What to watch: hard evidence the compounder story is real — organic growth accelerating toward high-single-digits, Process returning to growth, segment margin pushing into the mid-20s%, and divestiture proceeds visibly cutting the ~$20B net debt — which would justify the ~30x multiple and prompt an upgrade; the risk to respect is the narrative cracking: organic growth stalling, margin expansion fading, or leverage capping buybacks, which at ~30x earnings could re-rate the stock hard Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.